Cargando…
Glucagon-Like Peptide-1, Diabetes, and Cognitive Decline: Possible Pathophysiological Links and Therapeutic Opportunities
Metabolic and neurodegenerative disorders have a growing prevalence in Western countries. Available epidemiologic and neurobiological evidences support the existence of a pathophysiological link between these conditions. Glucagon-like peptide 1 (GLP-1), whose activity is reduced in insulin resistanc...
Autores principales: | Mossello, Enrico, Ballini, Elena, Boncinelli, Marta, Monami, Matteo, Lonetto, Giuseppe, Mello, Anna Maria, Tarantini, Francesca, Baldasseroni, Samuele, Mannucci, Edoardo, Marchionni, Niccolò |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124026/ https://www.ncbi.nlm.nih.gov/pubmed/21747826 http://dx.doi.org/10.1155/2011/281674 |
Ejemplares similares
-
Biomarkers of Alzheimer's Disease: From Central Nervous System to Periphery?
por: Mossello, Enrico, et al.
Publicado: (2010) -
Adiponectin, diabetes and ischemic heart failure: a challenging relationship
por: Baldasseroni, Samuele, et al.
Publicado: (2012) -
Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis
por: Monami, Matteo, et al.
Publicado: (2012) -
Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials
por: Monami, Matteo, et al.
Publicado: (2011) -
Rosiglitazone and Risk of Cancer: A meta-analysis of randomized clinical trials
por: Monami, Matteo, et al.
Publicado: (2008)